Havrix Nourrissons Et Enfants (Hepatitis A Virus (Inactivated), Aluminium Hydroxide)

Havrix Nourrissons Et Enfants is indicated for the prevention of hepatitis A infection in pediatric populations.

• Primary immunisation schedule for infants as recommended by national immunisation programmes.
• Booster doses for children who have completed the initial series.
• Use in outbreak settings to protect susceptible children.
• Administration to children with underlying chronic liver disease to reduce risk of severe hepatitis A.
• Integration with other routine childhood vaccines when scheduling immunisations.
• Option for subcutaneous administration when intramuscular injection is not feasible.

The safety profile of Havrix Nourrissons Et Enfants reflects the typical reactions observed with inactivated viral vaccines.

Common

• Mild pain, redness or swelling at the injection site.
• Low‑grade fever lasting 24‑48 hours.
• Transient fatigue or irritability.
• Headache or mild muscle aches.
• Nausea or mild gastrointestinal discomfort.

Serious

• Allergic reaction such as urticaria, angioedema or anaphylaxis.
• Neurological events including Guillain‑Barré syndrome, though very rare.
• Persistent high fever (>39°C) lasting more than 48 hours.
• Severe local reaction with extensive swelling or necrosis.
• Seizures or convulsions, extremely uncommon.

Before administering Havrix Nourrissons Et Enfants, healthcare providers should review the child’s medical history and consider specific precautionary measures.

• Known hypersensitivity to any vaccine component, especially aluminium hydroxide.
• History of severe allergic reaction to a previous dose of hepatitis A vaccine.
• Moderate or severe acute illness with fever at the time of vaccination.
• Immunocompromised conditions that may affect vaccine response.
• Pregnancy or breastfeeding status of the mother, if applicable.
• Use in children with chronic liver disease should be evaluated by a specialist.

Havrix Nourrissons Et Enfants may interact with other medicines or vaccines; awareness of potential interactions helps ensure safe administration.

Avoid

• Concurrent administration with live‑attenuated vaccines (e.g., measles‑mumps‑rubella) unless spaced appropriately.
• Simultaneous use of immunoglobulin products that could neutralise the vaccine antigen.

Use with caution

• Administration with other inactivated vaccines at the same visit; monitor for increased local reactions.
• Use in children receiving immunosuppressive therapy; antibody response may be reduced.
• Co‑administration with antipyretics may mask fever, but does not affect immunogenicity.